Beijing Balance Medical Technology Co. Ltd. Class A
SSSE:68819872.07
CNY
+1.99
(+2.84%)
Beijing Balance Medical Technology Co. Ltd. Class A
SSE:688198
(Shanghai Stock Exchange)
Recent
price
72.07
P/E
ratio
66.90
div
yld
1.12%
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Beijing Balance Medical Technology Co., Ltd. is a China-based medical technology enterprise engaged in the research, development, manufacture, and commercialization of animal-derived implantable biomaterials and interventional medical devices. The company operates across three primary business segments: Structural Heart Disease, Congenital Heart Disease Treatment, and Soft Tissue Repair. Its product portfolio includes prosthetic tissue heart valves, comprising bovine pericardial bioprosthetic valves, porcine aortic valves, and expand-restrictive surgical bioprosthetic valves; transcatheter valve intervention systems marketed under the Renatus brand, encompassing balloon-expandable transcatheter aortic valve systems and transcatheter valve-in-valve systems; annuloplasty rings and pulmonary valved conduits for valvuloplasty and outflow tract reconstruction; interventional congenital defect occlusion devices, including ventricular septal defect occluders, atrial septal defect occluders, and patent ductus arteriosus occluders; and biological tissue repair patches, covering cardiac surgical patches, neurosurgical dura mater patches, thoracic surgical patches, hernioplasty patches, and collagen-based injectable implants. The company primarily markets its devices to tertiary hospitals, cardiovascular specialty centers, and surgical institutions throughout the People's Republic of China. Founded in 2005, Beijing Balance Medical Technology Co., Ltd. is headquartered in Beijing, China, and operates through corporate subsidiaries including Bairen Medical (Jiangsu) Co., Ltd., Beijing Aibairui Biotechnology Co., Ltd., and Beijing Bairen Medical Equipment Co., Ltd. In recent developments, the company has accelerated the commercial expansion of its structural heart portfolio through the regulatory approval and nationwide clinical launch of its Renatus transcatheter aortic valve system and its Renatus transcatheter valve-in-valve system designed for failing bioprosthetic valves. Additionally, the company secured market clearances for its proprietary expand-restrictive surgical bioprosthetic valve and advanced cardiac biological patches, while advancing clinical trials for modular transcatheter mitral and aortic replacement platforms, transcatheter pulmonary valve systems, and ophthalmology surgical patches. To navigate regional volume-based procurement policies, the company has implemented a full-lifecycle valve management strategy that integrates both surgical and transcatheter technologies, while expanding production capacity and scaling its collagen biomaterials and regenerative soft tissue repair pipelines.